Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics amended its license agreement with BioAtla for CT-202, removing BioAtla's future milestone and royalty obligations in exchange for total payments of $6.5 million. The deal structure includes a $4.5 million upfront payment and a second installment of $2.0 million due by August 1, 2026.
Key figures
- Upfront payment
- $4.5 million
- Deferred payment
- $2.0 million
- Deferred payment date
- August 1, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.